This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $540,090 to The Regents of the University of California, San Francisco to conduct epigenetic analyses of osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The goal is to identify distinct osteosarcoma subtypes driven by specific transcription factor networks and characterize their biological basis and drug response vulnerabilities. The research aims to uncover novel strategies for combination therapy that can better address the intratumoral heterogeneity and treatment challenges associated with this disease. This 5-year project (4/1/2025 - 3/31/2030) represents an innovative, multi-omic approach to advancing the understanding and treatment of osteosarcoma, which has seen little progress in therapy over the past 40 years.
Generated 3/25/25, 3:04 AM